This company listing is no longer active
CDAK.Q Stock Overview
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Codiak BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0016 |
| 52 Week High | US$3.09 |
| 52 Week Low | US$0.0016 |
| Beta | 3.43 |
| 1 Month Change | -82.22% |
| 3 Month Change | -92.00% |
| 1 Year Change | -99.95% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Brokers Are Upgrading Their Views On Codiak BioSciences, Inc. (NASDAQ:CDAK) With These New Forecasts
Nov 08
Codiak BioSciences drops 31% postmarket on proposed stock offering
Sep 12Codiak cuts 37% of staff amid plans to reprioritize studies
Aug 30Codiak begins dosing in early-stage trial for liver, gastric, colorectal cancers
Jun 29Broker Revenue Forecasts For Codiak BioSciences, Inc. (NASDAQ:CDAK) Are Surging Higher
Mar 15Codiak BioSciences, Inc. (NASDAQ:CDAK) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Codiak BioSciences announces key promotions
Jun 15Codiak names Jennifer Wheler as chief medical officer
May 10Insider Buying: The Codiak BioSciences, Inc. (NASDAQ:CDAK) Independent Director Just Bought US$100k Worth Of Shares
Feb 18
What Percentage Of Codiak BioSciences, Inc. (NASDAQ:CDAK) Shares Do Insiders Own?
Jan 14Codiak posts positive initial phase 1 results for exoil-12
Dec 30Codiak BioSciences EPS beats by $13.68, beats on revenue
Nov 19Shareholder Returns
| CDAK.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -77.1% | -2.8% | -1.7% |
| 1Y | -99.9% | -0.2% | 22.4% |
Return vs Industry: CDAK.Q underperformed the US Biotechs industry which returned 2.5% over the past year.
Return vs Market: CDAK.Q underperformed the US Market which returned 12.6% over the past year.
Price Volatility
| CDAK.Q volatility | |
|---|---|
| CDAK.Q Average Weekly Movement | 61.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDAK.Q's share price has been volatile over the past 3 months.
Volatility Over Time: CDAK.Q's weekly volatility has increased from 36% to 62% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 102 | n/a | www.codiakbio.com |
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines.
Codiak BioSciences, Inc. Fundamentals Summary
| CDAK.Q fundamental statistics | |
|---|---|
| Market cap | US$58.93k |
| Earnings (TTM) | -US$17.42m |
| Revenue (TTM) | US$34.07m |
0.0x
P/S Ratio0.0x
P/E RatioIs CDAK.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDAK.Q income statement (TTM) | |
|---|---|
| Revenue | US$34.07m |
| Cost of Revenue | US$54.81m |
| Gross Profit | -US$20.74m |
| Other Expenses | -US$3.32m |
| Earnings | -US$17.42m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | -60.89% |
| Net Profit Margin | -51.13% |
| Debt/Equity Ratio | 66.0% |
How did CDAK.Q perform over the long term?
See historical performance and comparison